S. aureus

More documents

Recommendations

Info

Prevalence Density (Cases/10,000 patient-days) 10.0 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 P = 0.15 Total MRSA Healthcare Infections 8/03 - 7/04 9/04 - 7/05 9/05 - 7/06 8/06 - 7/07 8/07 - 7/08 8/08 - 7/09 ICU surveillance Universal surveillance P ≤ 0.001 Years A Robicsek et al, Ann Int Med 148:409-18, 2008 70% reduction in total MRSA disease during hospitalization and 30 days post-discharge 2 BSI in 3 hospitals LR Peterson et al, Decennial Meeting on Nosocomial Infections, Atlanta, 2010 Total
Includes all admissions (Community and Hospital onset) Data generated solely by capturing positive clinical cultures from LIS: Chart review (n=1,194) of all positive cultures found that 77.1% represented actual infection Universal surveillance begins P
Page 1 and 2: The Skin Microbiome - Clinical Labo
Page 3 and 4: Objectives • Review the relevance
Page 5 and 6: Skin Ecology - Dominance • Propio
Page 7 and 8: Microbiome of the Nose • S. aureu
Page 9 and 10: Risk for S. aureus Infection • Sy
Page 11 and 12: Review of Mupirocin Decolonization
Page 13 and 14: CDC Surveillance (2005) • Prospec
Page 15 and 16: US Infection Mortality 2005 FR DeLe
Page 17 and 18: Percent Positive on Admission 25.0
Page 19: NorthShore MRSA Program Began on Au
Page 23 and 24: Medical and Economic Outcome • Ex
Page 25 and 26: Cluster Randomized Trial of ICU: De
Page 28 and 29: Changing Prevalence of S. aureus in
Page 30 and 31: Results of Preoperative Screening f
Page 32 and 33: Prospective, Randomized Trial of S.

S. aureus

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?